Eli Lilly and Company $LLY Stock Position Lifted by Park Avenue Securities LLC

Key Points

• Park Avenue Securities increased its Eli Lilly stake by 4.7% in the third quarter, bringing its holdings to 37,258 shares valued at approximately $43.1 million. Institutional investors collectively own 82.53% of LLY.
• Wall Street remains broadly positive, with 24 analysts rating the stock a Buy and an average price target of $1,320.25, implying further upside from its reported $1,289.36 price.
• Eli Lilly reported quarterly EPS of $8.38 and revenue of $22.97 billion, surpassing estimates and recording 47.7% year-over-year revenue growth. The company also declared a $1.73 quarterly dividend, equal to a 0.5% annual yield.

Park Avenue Securities LLC grew its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 4.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 37,258 shares of the company's stock after acquiring an additional 1,656 shares during the quarter. Park Avenue Securities LLC's holdings in Eli Lilly and Company were worth $43,110,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in LLY. Bank of America Corp DE bought a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at approximately $13,522,666,000. Jupiter Topco LLC acquired a new position in Eli Lilly and Company during the 2nd quarter worth approximately $4,667,180,000. Fifth Third Bancorp increased its position in Eli Lilly and Company by 321.3% during the 1st quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company's stock worth $1,805,959,000 after purchasing an additional 1,497,423 shares in the last quarter. Corient Private Wealth LP acquired a new position in Eli Lilly and Company during the 2nd quarter worth approximately $764,116,000. Finally, BlackRock Inc. lifted its stake in Eli Lilly and Company by 1.6% in the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company's stock valued at $81,009,981,000 after purchasing an additional 1,046,558 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on LLY shares. JPMorgan Chase & Co. raised their target price on shares of Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the company an "overweight" rating in a research report on Monday, September 28th. UBS Group set a $1,376.00 target price on shares of Eli Lilly and Company in a research note on Friday, August 7th. Wells Fargo & Company upped their price target on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an "overweight" rating in a report on Thursday, August 6th. TD Cowen reiterated a "buy" rating and issued a $1,250.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, September 22nd. Finally, Bank of America raised their price objective on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a "buy" rating in a report on Friday, July 10th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company presently has an average rating of "Moderate Buy" and an average price target of $1,320.25.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,289.36 on Thursday. The stock's 50-day moving average is $1,192.52 and its 200-day moving average is $1,089.35. Eli Lilly and Company has a 1-year low of $809.63 and a 1-year high of $1,321.21. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The stock has a market cap of $1.21 trillion, a P/E ratio of 43.27, a price-to-earnings-growth ratio of 1.71 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.40 by $1.98. The business had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm's quarterly revenue was up 47.7% on a year-over-year basis. During the same quarter last year, the business earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 33.22 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company's payout ratio is presently 23.22%.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the company's stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the transaction, the executive vice president directly owned 11,875 shares in the company, valued at approximately $14,131,250. This represents a 29.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares of the company's stock, valued at $63,628,139.70. The trade was a 10.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is currently owned by company insiders.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Retatrutide produced a major clinical win over Ozempic. In a Phase 3 head-to-head trial, the investigational drug delivered average weight loss of approximately 44–47 pounds, or 20%–21%, after 80 weeks, compared with about 21 pounds for Ozempic. Retatrutide also reduced A1C by 2.2% versus 1.8% for Ozempic 2 mg. The results strengthen Lilly’s long-term position in the highly competitive obesity-drug market, although retatrutide is not yet approved. Lilly retatrutide trial results
• Positive Sentiment: A federal judge rejected Novo Nordisk’s effort to block Lilly’s weight-loss drug advertising, finding insufficient evidence of meaningful sales harm. The ruling preserves Lilly’s ability to market Zepbound and its obesity portfolio using the challenged campaign. Court rejects Novo advertising challenge
• Positive Sentiment: Lilly is broadening its pipeline beyond GLP-1 medicines, with Kisunla in neuroscience and Taltz and newer therapies in immunology expected to support growth. The company also licensed the SpeechDx Alzheimer’s dataset to advance speech-based disease markers. Lilly neuroscience and immunology outlook
• Positive Sentiment: Bernstein raised its Lilly price target to $1,450 from $1,385, reflecting continued confidence in the company’s growth outlook. Lilly also declared a quarterly dividend of $1.73 per share.
• Neutral Sentiment: Patrik Jonsson will retire as head of Lilly International at year-end 2026, with Ilya Yuffa taking over the expanded Lilly Global Markets role on January 1, 2027. The transition is planned, but investors may monitor execution as the company consolidates its global commercial structure. Lilly leadership transition
• Negative Sentiment: Investors face substantial earnings-event risk ahead of Thursday’s report. Analysts expect roughly $6.67 in earnings per share and $22.62 billion in revenue, while options markets imply a potentially large post-earnings move. Reports that recent EPS estimates have fallen sharply add to caution.
• Negative Sentiment: About 16% of employers are reportedly considering reducing coverage for weight-loss medicines. Any broader reimbursement pullback could pressure demand for Zepbound and limit the market’s near-term growth assumptions. Employer weight-loss drug coverage concerns
• Negative Sentiment: Two Massachusetts hospitals joined a lawsuit alleging Lilly’s digital tools may put patient privacy at risk. The claims remain unresolved, but adverse findings could create legal, regulatory, and reputational costs. Patient privacy lawsuit

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.